Page last updated: 2024-09-04

tipifarnib and ARS-1620

tipifarnib has been researched along with ARS-1620 in 1 studies

Compound Research Comparison

Studies
(tipifarnib)
Trials
(tipifarnib)
Recent Studies (post-2010)
(tipifarnib)
Studies
(ARS-1620)
Trials
(ARS-1620)
Recent Studies (post-2010) (ARS-1620)
309929418017

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)ARS-1620 (IC50)
GTPase KRasHomo sapiens (human)0.9
Heme oxygenase 2Homo sapiens (human)7.64
Quinone oxidoreductaseHomo sapiens (human)8.44
Synaptic vesicle membrane protein VAT-1 homologHomo sapiens (human)4.51

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Korzeniecki, C; Priefer, R1

Reviews

1 review(s) available for tipifarnib and ARS-1620

ArticleYear
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction

2021